StonvexLoading…
StonvexStonvexStonvexCore line items from IMAX's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $410.21M | $352.21M | $374.84M | $300.81M |
Operating Income | $84.23M | $43.86M | $50.40M | $-4.83M |
Net Income | $34.88M | $26.06M | $25.34M | $-22.80M |
EPS (Diluted) | $0.63 | $0.48 | $0.46 | $-0.40 |
Total Assets | $894.03M | $830.40M | $814.67M | $821.15M |
Total Liabilities | $466.30M | $452.18M | $469.08M | $491.39M |
Cash & Equivalents | $151.17M | $100.59M | $76.20M | $97.40M |
Free Cash Flow OCF − CapEx | $118.90M | $62.41M | $52.12M | $8.90M |
Shares Outstanding | 53.92M | 52.95M | 53.26M | 54.15M |